Related Party Transactions |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Related Party Transactions [Abstract] | |
| Related Party Transactions | 15. Related party transactions Prolaio transactions On February 24, 2025, the Company acquired 100% of the outstanding shares of Prolaio, Inc. At the time of the acquisition, Tassos Gianakakos, the Company’s Chief Executive Officer and member of its board of directors, also served as Prolaio, Inc.’s Chief Executive Officer and as a member of its board of directors and Jay Edelberg, the Company’s Chief Medical Officer, served as its Head of Research & Development and as a member of its board of directors. Mr. Gianakakos and Dr. Edelberg beneficially owned 55.7% and 17.1%, respectively, of Prolaio, Inc. at the time of its acquisition. Accordingly, Prolaio, Inc. was considered a related party during the pre-acquisition period, and the Prolaio acquisition itself constituted a related-party transaction. In addition, the amendment to the Agreement and Plan of Merger entered into on May 1, 2026 with the former Prolaio stockholders also constituted a related-party transaction. Refer to Note 5, “Acquisitions and Licensing Agreements” for additional information. During the pre-acquisition period, Prolaio, Inc. provided services to the Company utilizing its proprietary device, data monitoring, and analytics platform in support of the development of the Company’s cardiovascular product candidates. For the period from January 1, 2025 through February 24, 2025 (the Prolaio acquisition date), the Company made a prepayment of $0.3 million, and recognized $0.3 million of expense related to services performed by Prolaio, Inc. The Company had a prepaid expense balance of $0.3 million as of the acquisition date. Subsequent balances and transactions between Prolaio, Inc. and the Company are eliminated in consolidation. Common stock warrants In September 2025, in connection with the Series B financing, the Company issued warrants to purchase a total of 1,752,080 shares of common stock, at an exercise price of $13.41 per share, to ARCH Venture Fund XIII, L.P. and HRTG PV, L.P. (876,040 shares each), both principal stockholders of the Company. The Company recognized $7.4 million of warrant issuance expense related to these warrants for the three and nine months ended September 30, 2025. The warrants remained outstanding as of September 30, 2026. Refer to Note 10, “Stockholders' Equity” for additional information. |